Johnson & Johnson reported a 6.7 percent increase in its global sales to $81.6 billion for 2018. On an operational basis and in local currencies, they grew by 6.3 percent for the year and by 5.3 percent for the fourth quarter alone. Sales went up by 1.5 percent to $27.0 million for the year in the medical devices division, which includes its vision care segment, with a positive currency impact of 0.4 percent. The growth would have risen by 2.6 percent without the impact of the divestiture of the Lifescan business. The group's Acuvue line of contact lenses and surgical products outperformed. Sales of contact lenses grew by more than 4 percent globally in the fourth quarter, with strength in astigmatism and daily disposable lenses in the Oasys family. They were basically flat in the U.S. and rose by 7 percent outside the U.S., with strong penetration in emerging markets.